News

New Approval of Treatment for Young Children with Certain Brain Cancers On March 16, 2023, the U.S. Food and Drug Administration approved a new treatment combination that will now be available as an option for pediatric patients 1 year of age and older with low-grade glioma (LGG, grade 1 or 2) that have a mutation called BRAF V600E. This marks the first FDA approval of a […] March 21, 2023

How to Talk to Kids About Their Brain Tumor Diagnosis “Your child has a brain tumor.” It’s a phrase no parent wants to hear, yet more than 5,200 families will receive the news in 2023 alone.  This Childhood Cancer Awareness Month, NBTS is sharing stories from families in the brain tumor community. NBTS asked four families, “When faced with a brain tumor diagnosis, how did […] September 16, 2022

Q&A: A New Treatment Approved for Certain Brain Tumors In late June 2022, the U.S. Food and Drug Administration (FDA) granted accelerated approval to a new treatment combination that will now be available as an option for certain brain tumor patients. The approved combination of two oral drugs, called dabrafenib (brand name: Tafinlar) and trametinib (brand name: Mekinist), is for the treatment of advanced tumors […] August 9, 2022

New Brain Tumor Clinical Trials: January – June 2022 It can be hard to keep track of new clinical trial opportunities opening across the United States. There are many clinical trials actively enrolling patients, and this report provides a summary of the studies that have recently opened or started for primary brain tumor patients*. To learn more about each trial, and to contact the […] July 5, 2022

National Brain Tumor Society Statement on New Biden-Harris Cancer Moonshot Goals National Brain Tumor Society (NBTS), a leader in brain tumor patient advocacy, research, information, and support, was honored to represent the millions of Americans impacted by brain tumors every year at a White House event to reignite the Cancer Moonshot.  The following is a statement from NBTS chief executive officer, David Arons, on today’s announcement. […] February 2, 2022